SELECTA BIOSCIENCES INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
SELECTA BIOSCIENCES INC. - More news...
SELECTA BIOSCIENCES INC. - More news...
- Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference
- Selecta Biosciences, Inc. - SELB Stock Chart Technical Analysis for 06-12-2020
- Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
- Selecta Biosciences to Present at the Jefferies Virtual Healthcare Conference
- Selecta Biosciences Reports First Quarter 2020 Financial Results
- Selecta Biosciences to Present at the Bank of America Merrill Lynch 2020 Health Care Conference
- Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Recent Operational Highlights
- Selecta Biosciences Appoints Dr. Goran Ando to its Board of Directors
- Selecta Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
- Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results
- Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
- Selecta Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
- Selecta Biosciences, Inc. - SELB Stock Chart Technical Analysis for 02-05-2020
- Selecta Biosciences, Inc. - SELB Stock Chart Technical Analysis for 01-07-2020
- Selecta Biosciences, Inc. - SELB Stock Chart Technical Analysis for 12-20-2019
- Selecta Biosciences, Inc. - SELB Stock Chart Technical Analysis for 12-19-2019
- AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
- AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
- Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212
- Selecta Biosciences Announces $70 Million Private Placement
- Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors
- Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout
- Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
- Selecta Biosciences Announces Date of Third Quarter 2019 Financial Results Conference Call
- Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting
- Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress
- Selecta Biosciences to Participate in Two Investor Conferences in October
- Selecta Biosciences to Present at the Janney Healthcare Conference
- Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership